Switzerland: Research Collaboration Highly Innovative Human Aerosol Test Platform Allows Test on Lung Models
Within the framework of a collaboration agreement, Philip Morris International (PMI) and Tissuse plan to utilize PMI’s Inhales technology in combination with Tissuse’s proprietary Multi-Organ-Chip (MOC) platform to enable inhalation exposure of functional human tissues in homeostasis at minute scale in vitro.
Neuchâtel/ Switzerland; Berlin/Germany — In order to emulate the entire human respiratory tract with regard to dimension and architecture, PMI and Tissuse want to develop a highly innovative integrated human aerosol test platform.
PMI has established a platform that perfectly matches the architecture and characteristics of the human respiratory tract (Inhales). Tissuse has established the widely used Humimic Multi-Organ-Chip (MOC) platform, which enables functional human tissue response in vitro. A plug & play interface between the two technologies will allow physiologically relevant exposure to complex aerosols in the background of an in vivo-like organization and breathing performance of the human lungs. The novel integrated test platform will allow acute and subchronic tests on lung models in combination with miniaturized human liver equivalents, enabling assessment of local effects on the biological barrier of lung epithelia, penetration of substances into blood circulation, and eventual systemic effects. Altogether, the platform is to provide a highly predictive model for assessing respiratory toxicity and systemic human effects of inhaled aerosols and their constituents, such as environmental toxins, smoke particles, airborne pathogens, and inhalable medications.